Cargando…
Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor
OBJECTIVES: Chronic hyperlipidemia and hyperglycemia are characteristic features of type 2 diabetes (T2DM) that are thought to cause or contribute to β-cell dysfunction by “glucolipotoxicity.” Previously we have shown that acute treatment of pancreatic islets with fatty acids (FA) decreases acetylch...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641685/ https://www.ncbi.nlm.nih.gov/pubmed/29031723 http://dx.doi.org/10.1016/j.molmet.2017.07.017 |
_version_ | 1783271274068312064 |
---|---|
author | Doliba, Nicolai M. Liu, Qin Li, Changhong Chen, Pan Liu, Chengyang Naji, Ali Matschinsky, Franz M. |
author_facet | Doliba, Nicolai M. Liu, Qin Li, Changhong Chen, Pan Liu, Chengyang Naji, Ali Matschinsky, Franz M. |
author_sort | Doliba, Nicolai M. |
collection | PubMed |
description | OBJECTIVES: Chronic hyperlipidemia and hyperglycemia are characteristic features of type 2 diabetes (T2DM) that are thought to cause or contribute to β-cell dysfunction by “glucolipotoxicity.” Previously we have shown that acute treatment of pancreatic islets with fatty acids (FA) decreases acetylcholine-potentiated insulin secretion. This acetylcholine response is mediated by M3 muscarinic receptors, which play a key role in regulating β-cell function. Here we examine whether chronic FA exposure also inhibits acetylcholine-potentiated insulin secretion using mouse and human islets. METHODS: Islets were cultured for 3 or 4 days at different glucose concentration with 0.5 mM palmitic acid (PA) or a 2:1 mixture of PA and oleic acid (OA) at 1% albumin (PA/BSA molar ratio 3.3). Afterwards, the response to glucose and acetylcholine were studied in perifusion experiments. RESULTS: FA-induced impairment of insulin secretion and Ca(2+) signaling depended strongly on the glucose concentrations of the culture medium. PA and OA in combination reduced acetylcholine potentiation of insulin secretion more than PA alone, both in mouse and human islets, with no evidence of a protective role of OA. In contrast, lipotoxicity was not observed with islets cultured for 3 days in medium containing less than 1 mM glucose and a mixture of glutamine and leucine (7 mM each). High glucose and FAs reduced endoplasmic reticulum (ER) Ca(2+) storage capacity; however, preserving ER Ca(2+) by blocking the IP3 receptor with xestospongin C did not protect islets from glucolipotoxic effects on insulin secretion. In contrast, an inhibitor of casein kinase 2 (CK2) protected the glucose dependent acetylcholine potentiation of insulin secretion in mouse and human islets against glucolipotoxicity. CONCLUSIONS: These results show that chronic FA treatment decreases acetylcholine potentiation of insulin secretion and that this effect is strictly glucose dependent and might involve CK2 phosphorylation of β-cell M3 muscarinic receptors. |
format | Online Article Text |
id | pubmed-5641685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-56416852017-10-23 Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor Doliba, Nicolai M. Liu, Qin Li, Changhong Chen, Pan Liu, Chengyang Naji, Ali Matschinsky, Franz M. Mol Metab Original Article OBJECTIVES: Chronic hyperlipidemia and hyperglycemia are characteristic features of type 2 diabetes (T2DM) that are thought to cause or contribute to β-cell dysfunction by “glucolipotoxicity.” Previously we have shown that acute treatment of pancreatic islets with fatty acids (FA) decreases acetylcholine-potentiated insulin secretion. This acetylcholine response is mediated by M3 muscarinic receptors, which play a key role in regulating β-cell function. Here we examine whether chronic FA exposure also inhibits acetylcholine-potentiated insulin secretion using mouse and human islets. METHODS: Islets were cultured for 3 or 4 days at different glucose concentration with 0.5 mM palmitic acid (PA) or a 2:1 mixture of PA and oleic acid (OA) at 1% albumin (PA/BSA molar ratio 3.3). Afterwards, the response to glucose and acetylcholine were studied in perifusion experiments. RESULTS: FA-induced impairment of insulin secretion and Ca(2+) signaling depended strongly on the glucose concentrations of the culture medium. PA and OA in combination reduced acetylcholine potentiation of insulin secretion more than PA alone, both in mouse and human islets, with no evidence of a protective role of OA. In contrast, lipotoxicity was not observed with islets cultured for 3 days in medium containing less than 1 mM glucose and a mixture of glutamine and leucine (7 mM each). High glucose and FAs reduced endoplasmic reticulum (ER) Ca(2+) storage capacity; however, preserving ER Ca(2+) by blocking the IP3 receptor with xestospongin C did not protect islets from glucolipotoxic effects on insulin secretion. In contrast, an inhibitor of casein kinase 2 (CK2) protected the glucose dependent acetylcholine potentiation of insulin secretion in mouse and human islets against glucolipotoxicity. CONCLUSIONS: These results show that chronic FA treatment decreases acetylcholine potentiation of insulin secretion and that this effect is strictly glucose dependent and might involve CK2 phosphorylation of β-cell M3 muscarinic receptors. Elsevier 2017-08-04 /pmc/articles/PMC5641685/ /pubmed/29031723 http://dx.doi.org/10.1016/j.molmet.2017.07.017 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Doliba, Nicolai M. Liu, Qin Li, Changhong Chen, Pan Liu, Chengyang Naji, Ali Matschinsky, Franz M. Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor |
title | Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor |
title_full | Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor |
title_fullStr | Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor |
title_full_unstemmed | Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor |
title_short | Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor |
title_sort | inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: protection by casein kinase 2 inhibitor |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641685/ https://www.ncbi.nlm.nih.gov/pubmed/29031723 http://dx.doi.org/10.1016/j.molmet.2017.07.017 |
work_keys_str_mv | AT dolibanicolaim inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor AT liuqin inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor AT lichanghong inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor AT chenpan inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor AT liuchengyang inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor AT najiali inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor AT matschinskyfranzm inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor |